IP Library › Granted Patent US 11,957,747
Granted Patent B2
US 11,957,747 · App. 17/143,953 · Granted Apr 16, 2024

Vector production

Inventors: Alessio Cantore (Milan, IT); Angelo Leone Lombardo (Milan, IT); Luigi Naldini (Milan, IT)
Assignees: Ospedale San Raffaele S.r.l.; Fondazione Telethon ETS
A61K39/12C12N7/04C12N15/86A61K2121/00C12N2740/10052C12N2740/16041C12N2740/16052
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,957,747
App. No.
17/143,953
Granted
Apr 16, 2024
Kind
B2
Abstract

An enveloped viral particle producer or packaging cell, wherein the cell is genetically engineered to decrease expression of MHC-I on the surface of the cell.

Claims (18)

1. An enveloped viral particle producer or packaging cell, wherein the producer or packaging cell is genetically engineered to decrease expression of MHC-1 on the surface of the producer or packaging cell, wherein the producer or packaging cell comprises one or more nucleic acid sequences encoding one or more viral particle structural proteins, and wherein:

(a) the packaging cell lacks a vector encoding a viral genome; whereas

(b) the producer cell further comprises a vector encoding a viral genome comprising a therapeutic nucleotide of interest.

2. The enveloped viral particle producer or packaging cell of claim 1 , wherein the cell comprises a genetically engineered disruption of a gene encoding β2-microglobulin.

3. The enveloped viral particle producer or packaging cell of claim 1 , wherein the cell comprises a genetically engineered disruption of one or more genes encoding an MHC-1α chain.

4. The enveloped viral particle producer or packaging cell of claim 1 , wherein the cell is a HEK-293 cell or a derivative thereof.

5. The enveloped viral particle producer or packaging cell of claim 4 , wherein the cell is a HEK-293T or a HEK-293 T-REx cell.

6. The enveloped viral particle producer or packaging cell of claim 1 , wherein the enveloped viral particle is a retrovirus, herpes simplex virus, vaccinia virus, hepadnavirus, togavirus, flavivirus, arenavirus, coronavirus, orthomyxovirus, paramyxovirus, bunyavirus, bornavirus, rhabdovirus, filovirus or derived therefrom.

7. The enveloped viral particle producer or packaging cell of claim 1 , wherein the enveloped viral particle is a lentivirus or derived therefrom.

8. The enveloped viral particle producer or packaging cell of claim 1 , wherein the therapeutic nucleotide of interest encodes coagulation factor VIII or factor IX, or engineered derivatives thereof; or beta-globin.

9. The enveloped viral particle producer or packaging cell of claim 1 , wherein the cell comprises one or more nucleic acid sequences encoding a viral capsid protein and/or a viral envelope protein.

10. The enveloped viral particle producer or packaging cell of claim 1 , wherein the viral particle is a retroviral particle, and wherein the cell comprises one or more nucleic acid sequences encoding one or more proteins selected from the group consisting of Gag, Pol and Env.

11. The enveloped viral particle producer or packaging cell of claim 10 , wherein the viral particle is a lentiviral particle.

12. The enveloped viral particle producer or packaging cell of claim 11 , wherein the cell further comprises a nucleic acid sequence encoding Rev.

13. A method of producing enveloped viral particles comprising the steps:

(a) providing an enveloped viral particle producer cell according to claim 1 ; and

(b) culturing the cell under conditions suitable for the production of the enveloped viral particles.

14. The method of claim 13 , wherein the enveloped viral particles are substantially devoid of surface-exposed MHC-1 molecules.

Assignments (2)
CHANGE OF NAME Recorded Nov 29, 2023
From: FONDAZIONE TELETHON
To: FONDAZIONE TELETHON ETS
Reel/Frame 066762/0574 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2021
From: CANTORE, ALESSIO; LOMBARDO, ANGELO LEONE; NALDINI, LUIGI
To: OSPEDALE SAN RAFFAELE S.R.L.; FONDAZIONE TELETHON
Reel/Frame 055108/0261 →
Priority Claims (1)
GB 1412494 · Jul 14, 2014 · national
Continuity (2)
Continuation 15325124
Related Publication 20210346489A1 · Nov 11, 2021